Great stuff, RIZ and MY69Z! This is why MARAVIROC
Post# of 155125
Was sidelined. Everyone thought this new entry inhibitor when it came out almost 20 years ago was going to be a game changer and it was temporarily until HIV replicating on an order of trillions of new copies very quickly was able to switch phenotypes and enter through CXCR4. Those patients who had been achieving viral load suppression With MVC later developed what appeared to be mutation and that allowed HIV to enter cells through another doorway called CXCR four instead of CCR five making those patients no longer able to take MVC.
This has been a problem. I’ve been thinking about with LL for quite some time and could possibly explain the blips, but I have to think about that a little bit longer.
Might also be why the FDA was trying to marginalized the molecule to just highly treatment experienced HIV patients. Salvage patients if you will.
So enter ibalizumab paired with LL and you now have CXCR4 and CCR five entry points for HIV covered which ultimately does not allow HIV to enter T cells and replicate and destroy the immune system

